Merck ADC, licensed from China, hits mark in first big global trial

Merck said Sac-TMT met its global Phase 3 endometrial cancer endpoint, improving overall and progression-free survival versus chemotherapy at an early scheduled data check. The success reinforces Merck’s $70B post-Keytruda growth strategy and adds clinical validation ahead of ASCO lung-cancer data, with RBC estimating Sac-TMT could generate $2.6B in sales by 2030 and $7.2B by 2034. The results may help differentiate Sac-TMT from competing TROP2 antibody-drug conjugates from Gilead and AstraZeneca/Daiichi Sankyo.

Analysis

This is less a single-drug story than an option on Merck’s post-Keytruda revenue bridge. The important signal is that the asset is showing multitumor applicability before commercial evidence is available, which increases the probability it becomes a platform franchise rather than a niche launch. For MRK, that matters because the market is still discounting a patent-cliff gap; every credible oncology readout that expands the addressable pool reduces the terminal-multiple compression risk.

The second-order implication is competitive pressure on the TROP2 field. If Sac-TMT continues to separate on efficacy while maintaining tolerability, it can force prescribers to treat the class less like a commodity ADC category and more like differentiated regimens by line of therapy and tumor biology. That would pressure GILD and AZN/Daiichi-like peers not just on share, but on future combo trial economics, where weaker assets become harder to sequence and may require higher trial spend to stay relevant.

The near-term catalyst path is asymmetric: the next 1-3 months are about ASCO confirmation and regulatory posture in China, but the bigger valuation inflection is over 12-24 months as investors start underwriting a credible multibillion-dollar launch curve. The main downside is class-wide ADC toxicity or lack of reproducibility across tumor types; if later datasets show narrower breadth, the current enthusiasm could unwind quickly because the bull case relies on breadth, not just one indication. Also, the market may be overpricing terminal sales too early, since manufacturing scale, payer access, and sequencing against existing ADCs usually delay peak penetration by several years.

Key Decisions for Investors

• Long MRK vs short GILD as a 6-12 month relative-value pair: MRK has the cleaner upside to a post-Keytruda growth bridge, while GILD faces incremental franchise pressure if TROP2 differentiation widens; target 8-12% pair alpha with the short acting as a hedge against broader biotech beta.
• Buy MRK call spreads expiring after ASCO/next major data check (3-6 months): structure for upside continuation with limited premium outlay; risk/reward is attractive if the market starts capitalizing Sac-TMT as a pipeline platform rather than a single readout.
• Short AZN against MRK on a 3-6 month horizon if you want a tighter competitive expression: AZN’s ADC exposure is more vulnerable to any evidence that Sac-TMT offers better efficacy-tolerability balance in TROP2 settings; use a modest size because the read-through is indirect.
• If MRK rallies hard into the next data event, trim 25-35% and hold a residual core: the market will likely front-run long-dated Sac-TMT sales, and any disappointment in breadth or safety could mean a fast retrace.
• For investors wanting cleaner biotech beta, consider a basket long on MRK and short a small equal-weight basket of TROP2 peers/adjacent ADC leaders; the thesis is dispersion, not sector direction, over the next 1-2 quarters.